MEDI 85 |
| Approximately 85% of colon cancers are thought to result from point mutations in checkpoint proteins. These colon cancers are categorized as Microsatellite Stable (MSS), and are treatable with a current drug on the market, 5-Fluorouracil (5-FU). The remaining 15% of colon cancers are thought to occur due to mutations in repetitive sequences within microsatellite regions in growth regulator proteins. These mutations cause instability in these regions, thus lending the name Micosatellite Instability (MSI). These MSI cancers are resistant to current chemotheraputic drugs. In addition, 5-Fluorouracil (5-FU) has a number of intolerable side effects, thus it is desirable to find new structures that target both MSS and MSI cancer pathways. It has been shown that Sansalvamide A (San A), which is a depsipeptide isolated from a marine fungus (Fusarium ssp.), exhibits anti-tumor activity. We have shown that a number of derivatives are potent against two MSS and two MSI colon cancer cell lines. Inhibiting growth of all four colon cancers suggests a common mechanism of action. In addition to perhaps finding a compound that inhibits four colon cancers, two of these colon cancer cell lines are chemotherapeutically resistant. Thus, we may have found a unique pharmacophore to inhibit drug resistant colon cancers. |
|
General Poster Session
7:00 PM-9:00 PM, Sunday, 10 September 2006 Moscone Center -- Hall D, Poster
Division of Medicinal Chemistry |